Yes, they could definitely be complimentary.

Vascepa for CAD or high risk of CAD patients with high triglyceride patients.

Apabetalone for low HDL diabetics with CAD.

I could certainly imagine a scenario where a patient is on a statin/Apabetalone and Vascepa.

Apabetalone would likely offer much more potential to big Pharma with respect to other indications and label expansion.

bfw